Samumed announces modulation of Wnt pathway for potential cartilage regeneration

November 09, 2015

SAN FRANCISCO--November 9, 2015--At the American College of Rheumatology (ACR) Annual Meeting, Samumed unveiled groundbreaking pre-clinical and clinical research that demonstrated successful modulation of the Wnt pathway for potential applications in regenerative medicine. Samumed researchers have developed an injectable investigational drug that inhibits the Wnt pathway, causing endogenous stem cells to regenerate knee cartilage in animals. Clinical data indicate that the same investigational drug may slow joint space narrowing and possibly increase joint space in the knee. Clinicians generally perceive an increase in joint space as evidence of preservation or regrowth of cartilage.

"The results of our Phase I study of SM04690 for the treatment of osteoarthritis of the knee are very encouraging," said Yusuf Yazici, M.D., Chief Medical Officer of Samumed. "We believe that the clinical trial results we have seen to date, combined with the success of our animal results, demonstrate that our technology could potentially be the basis of a safe and effective treatment for the millions of patients suffering from osteoarthritis of the knee."

OSTEOARTHRITIS CLINICAL TRIAL

Samumed recently concluded a 24 week placebo-controlled, double-blind, randomized Phase I clinical trial, studying the safety and preliminary efficacy of SM04690 in patients with moderate to severe osteoarthritis of the knee. Subsequently, Samumed began enrollment in an approximately 400-patient Phase II clinical trial. SM04690 is a small molecule inhibitor of the Wnt pathway administered via intra-articular (IA) injection.

In the Phase I trial, a total of 61 subjects were enrolled across 3 dose cohorts, in ratios of 4:1 treatment to placebo, with each subject receiving a single IA injection (i.e., 16 patients injected with SM04690 versus 4 administered placebo at each of the 3 dose levels). The study's primary objectives were to evaluate the safety and tolerability of SM04690, determine the dose-limiting toxicities, and assess its pharmacokinetic behavior. The study's secondary exploratory objective was to estimate clinical response to treatment, using, among other measures, change from baseline for function, pain and stiffness scores using the Western Ontario and McMaster Universities Arthritis Index (WOMAC), and physician global assessment of disease activity. Magnetic resonance imaging (i.e., MRI) at 12 weeks and 24 weeks and radiographic (i.e., x-ray) imaging data at 24 weeks were also collected to study safety and potential disease modification effect.

At the ACR Annual Meeting, the company presented two posters relating to the 12 week safety and efficacy interim results from this Phase I trial, as well as the preliminary 24 week safety and radiographic imaging results (see Poster # 312: Safety, Efficacy and Biomarker Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study & Poster # 313: Magnetic Resonance Imaging Outcomes Using an Intra-Articular Injection (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study). Radiographic imaging suggests a slowing/stopping of joint space narrowing compared to placebo, with one dose level demonstrating statistically significant improved joint space width. The results also suggested that a single IA injection with SM04690 appeared to be safe and potentially effective in improving function and reducing pain for patients with osteoarthritis of the knee. More than 9 million Americans have symptomatic osteoarthritis of the knee. According to the Arthritis Foundation, osteoarthritis (in any joint) affects 27 million Americans--more than 10 percent of the U.S. adult population--and is the most common cause of disability in the United States.

PRECLINICAL RESEARCH RESULTS

Osteoarthritic joints are characterized by degradation of the articular cartilage, which provides the cushioning between bones, and by bony protrusions called osteophytes, which interfere with function and exacerbate the pain associated with osteoarthritis. An overactive Wnt pathway in the affected joint causes the formation of more (spurious) bone instead of (healthy) cartilage, leading to pain, loss of function, stiffness, and deformity.

"The Wnt pathway has been extensively studied because it is a master regulator of tissue regeneration. Our research has uncovered previously-unknown targets in the Wnt pathway and we are developing small molecule drugs that stimulate tissue repair and regeneration," said John Hood, Ph.D., Chief Scientific Officer and Co-Founder of Samumed.

Samumed has demonstrated that its investigational compound SM04690 modulated the Wnt pathway in cellular and animal models, leading endogenous adult stem cells to differentiate into cartilage-forming chondrocyte cells (see Dr. Hood's presentation at the ACR Annual Meeting: Discovery of an Intra-Articular Injection Small Molecule Inhibitor of the Wnt Pathway (SM04690) As a Potential Disease Modifying Treatment for Knee Osteoarthritis). Samumed has shown that in vitro inhibition of the Wnt pathway caused adult human mesenchymal stem cells to differentiate into chondrocyte cells at a rate 50 fold higher than control, while simultaneously reducing the levels of cartilage degrading protease enzymes by a similar factor. In animal studies modeling osteoarthritis of the knee, the net effect of the inhibition of the Wnt pathway has been the regeneration of articular cartilage and suppression of inflammation in the knee joints of the study animals.
-end-
ABOUT SAMUMED, LLC

Based in San Diego, CA, Samumed is a pharmaceutical platform company focused on advancing regenerative medicine and oncology applications through research and innovation. Samumed has discovered new targets and biological processes in the Wnt pathway, allowing the team to develop small molecule drugs that potentially address numerous degenerative conditions as well as many forms of cancer.

Rasky Baerlein Strategic Communications

Related Osteoarthritis Articles from Brightsurf:

Major savings possible with app-based osteoarthritis treatment
Osteoarthritis treatment conducted digitally via an app costs around 25% of what conventional care costs, according to a study from Lund University in Sweden published in the research journal PLOS ONE.

New approach to treating osteoarthritis advances
Injections of a natural 'energy' molecule prompted regrowth of almost half of the cartilage lost with aging in knees, a new study in rodents shows.

Bone drug may be beneficial for knee osteoarthritis
Bisphosphonates (a class of drugs that prevent the loss of bone density and used to treat osteoporosis and similar diseases) appear to be safe and beneficial for osteoarthritis patients.

Certain jobs linked to higher risk of knee osteoarthritis
Workers in jobs that typically involve heavy lifting, frequent climbing, prolonged kneeling, squatting, and standing face an increased risk of developing knee osteoarthritis.

App helps reduce osteoarthritis pain
By performing a few simple physical exercises daily, and receiving information about their disease regularly, 500 osteoarthritis patients were able to on average halve their pain in 6 months -- and improve their physical function.

Osteoarthritis can increase your risk for social isolation
In a study published in the Journal of the American Geriatrics Society, researchers examined information from the European Project on OSteoArthritis (EPOSA) study.

High rates of opioid prescriptions for osteoarthritis
Opioids work against severe pain but the risks of side effects and addiction are high.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

3D printing may help treat osteoarthritis
In a Journal of Orthopaedic Research study, scientists used 3D printing to repair bone in the joints of mini-pigs, an advance that may help to treat osteoarthritis in humans.

Finger joint enlargements may be linked to knee osteoarthritis
Heberden's nodes (HNs) are bony enlargements of the finger joints that are readily detectable in a routine physical exam and are considered hallmarks of osteoarthritis.

Read More: Osteoarthritis News and Osteoarthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.